0.32
+0.0164(+5.39%)
Currency In USD
| Previous Close | 0.3 |
| Open | 0.32 |
| Day High | 0.35 |
| Day Low | 0.31 |
| 52-Week High | 3.67 |
| 52-Week Low | 0.22 |
| Volume | 166,658 |
| Average Volume | 554,607 |
| Market Cap | 12.51M |
| PE | -0.16 |
| EPS | -2.06 |
| Moving Average 50 Days | 0.28 |
| Moving Average 200 Days | 0.49 |
| Change | 0.02 |
If you invested $1000 in Athira Pharma, Inc. (ATHA) since IPO date, it would be worth $18.73 as of June 17, 2025 at a share price of $0.32. Whereas If you bought $1000 worth of Athira Pharma, Inc. (ATHA) shares 3 years ago, it would be worth $37.26 as of June 17, 2025 at a share price of $0.32.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
GlobeNewswire Inc.
May 13, 2025 3:00 PM GMT
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a cl
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
GlobeNewswire Inc.
Dec 06, 2024 10:30 PM GMT
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinica
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
GlobeNewswire Inc.
Nov 07, 2024 9:05 PM GMT
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical compa